<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25098">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01958814</url>
  </required_header>
  <id_info>
    <org_study_id>PHAO11-PD / BANNISTER</org_study_id>
    <secondary_id>2011-004802-20</secondary_id>
    <nct_id>NCT01958814</nct_id>
  </id_info>
  <brief_title>Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.</brief_title>
  <acronym>BANNISTER</acronym>
  <official_title>Controlled Randomized Double-blind Study Comparing Salbutamol and Placebo Via Aerosol in Chronic Obstructive Respiratory Insufficiency in Exacerbartion Treated With Noninvasive Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      randomized double-blind controlled study in parallel groups
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Collection at the bedside spirometric values​​</measure>
    <time_frame>gross change in forced expiratory volume in one second from the beginning of salbutamol or placebo and 15 min after the start</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>gross change in vital capacity of peak expiratory flow rate, the ratio of FEV, forced expiratory flow</measure>
    <time_frame>between the median baseline and 15 min after the start of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gross change in respiratory rate, heart rate and systolic and diastolic blood pressure</measure>
    <time_frame>between baseline and 15 min after the start of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gross change in dyspnea</measure>
    <time_frame>between baseline and 15 min after the start of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Clinically Significant Increase in Maximum Expiratory Volume Per Second</condition>
  <arm_group>
    <arm_group_label>Salbutamol - Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>salbutamol at M0 and M60 placebo administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Salbutamol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo at M0 and M60 salbutamol administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol</intervention_name>
    <arm_group_label>Salbutamol - Placebo</arm_group_label>
    <arm_group_label>Placebo - Salbutamol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo : physiological serum</intervention_name>
    <arm_group_label>Salbutamol - Placebo</arm_group_label>
    <arm_group_label>Placebo - Salbutamol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient over 18 years old

          -  Patient with BPCO, defined:

               -  by an irreversible obstructive syndrome

               -  and\or by different arguments (histories, symptoms, physical examination,
                  thoracic radiography, gas of the blood)

          -  Decompensation of this BPCO in the form of acute respiratory failure

          -  No argument for a dominant acute left cardiac insufficiency

          -  Consent signed by the patient

          -  Patient with national health assurance

        Exclusion Criteria:

          -  Contraindications in the not invasive ventilation

          -  Patient not volunteer for the realization of the spirometry

          -  Precautions for use of ß2 mimetic (engrave hyperthyroidism)

          -  Under guardianship patient or protection of justice

          -  Pregnant patient
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pierre-François DEQUIN, MD-PhD</last_name>
    <phone>02.47.47.84.45</phone>
    <email>dequin@med.univ-tours.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie COUDRAY</last_name>
    <phone>02.47.47.46.64</phone>
    <email>marie.coudray@med.univ-tours.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de Réanimation Médicale - CHR d'Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry BOULAIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thierry BOULAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-François DEQUIN</last_name>
      <phone>02.47.47.84.45</phone>
      <email>dequin@med.univ-tours.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-François DEQUIN, MD - PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 8, 2013</lastchanged_date>
  <firstreceived_date>October 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Albuterol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
